OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Forecast, Price & News $38.25 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$38.25▼$38.2550-Day Range$30.38▼$41.7552-Week Range$11.83▼$41.75VolumeN/AAverage Volume399 shsMarket Capitalization$1.97 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest About Zealand Pharma A/S (OTCMKTS:ZLDPF) StockZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLDPF Stock News HeadlinesJune 6, 2023 | finance.yahoo.comRecent Price Trend in Zealand Pharma A/S (ZLDPF) is Your Friend, Here's WhyJune 6, 2023 | finance.yahoo.comZealand Pharma to Participate in Upcoming Healthcare ConferencesJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 31, 2023 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at May 31, 2023May 29, 2023 | americanbankingnews.comZealand Pharma A/S (OTCMKTS:ZLDPF) Sees Significant Drop in Short InterestMay 11, 2023 | finance.yahoo.comZealand Pharma Announces Financial Results for the First Quarter of 2023May 10, 2023 | benzinga.comObesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli LillyMay 10, 2023 | msn.comBoehringer, Zealand's drug helps cut weight up to 14.9%, meets phase 2 trial's goalJune 8, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 10, 2023 | finance.yahoo.comUPDATE 2-Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trialMay 10, 2023 | finance.yahoo.comBoehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweightMay 4, 2023 | finance.yahoo.comZealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 ResultsApril 28, 2023 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at April 28, 2023April 3, 2023 | finance.yahoo.comZealand Pharma A/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq CopenhagenApril 2, 2023 | americanbankingnews.comContrasting Zealand Pharma A/S (OTCMKTS:ZLDPF) & Melco International Development (OTCMKTS:MDEVF)March 31, 2023 | finance.yahoo.comTotal number of shares and voting rights in Zealand Pharma at March 31, 2023March 30, 2023 | finance.yahoo.comZealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billionMarch 30, 2023 | americanbankingnews.comZealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Increase in Short InterestMarch 16, 2023 | reuters.comNew Zealand's Fonterra posts 50% jump in half-year profitMarch 15, 2023 | money.usnews.comNew Zealand Fourth-Quarter GDP Below Expectations as It Falls 0.6%March 3, 2023 | finance.yahoo.comCorrection: Zealand Pharma convenes its Annual General Meeting 2023February 27, 2023 | msn.comNew Zealand set England 258 to win second Test after Williamson centuryFebruary 24, 2023 | yahoo.comThe Ultimate New Zealand Packing ListFebruary 24, 2023 | finance.yahoo.comZealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022February 18, 2023 | msn.comBroad fires England to verge of first Test win over New ZealandFebruary 18, 2023 | msn.comWatch: New Zealand troops supply aid to storm-hit townsFebruary 12, 2023 | cnn.comSchools to close, flights canceled as New Zealand’s largest city braces for Cyclone GabrielleSee More Headlines ZLDPF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLDPF Company Calendar Last Earnings5/11/2023Today6/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CUSIPN/A CIKN/A Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-170,220,000.00 Net Margins-1,140.99% Pretax Margin-972.87% Return on Equity-164.35% Return on Assets-74.39% Debt Debt-to-Equity Ratio0.58 Current Ratio7.53 Quick Ratio7.47 Sales & Book Value Annual Sales$14.73 million Price / Sales133.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book17.08Miscellaneous Outstanding Shares51,510,000Free FloatN/AMarket Cap$1.97 billion OptionableNot Optionable Beta0.68 Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 49)Pres & CEO Comp: $733.86kMs. Henriette WennickeChief Financial OfficerMr. Ivan Mourits Moller (Age 51)Chief Operating Officer Lani Pollworth MorvanInvestor Relations & Communications OfficerMr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder ChahilSr. VP & Gen. CounselMs. Christina Sonnenborg Bredal (Age 38)Sr. VP and Global Head of People & Organization Ms. Hanne Heidenheim Bak (Age 70)Sr. Project Director, R&D Operations Mang. and Employee Representative Director Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsMore ExecutivesKey CompetitorsNihon KohdenOTCMKTS:NHNKYClinigen GroupOTCMKTS:CLIGFPharma MarOTCMKTS:PHMMFOxford BiomedicaOTCMKTS:OXBDFSemperit AktiengesellschaftOTCMKTS:SEIGYView All Competitors ZLDPF Stock - Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZLDPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZLDPF, but not buy additional shares or sell existing shares. View ZLDPF analyst ratings or view top-rated stocks. How have ZLDPF shares performed in 2023? Zealand Pharma A/S's stock was trading at $28.18 on January 1st, 2023. Since then, ZLDPF shares have increased by 35.7% and is now trading at $38.25. View the best growth stocks for 2023 here. Are investors shorting Zealand Pharma A/S? Zealand Pharma A/S saw a decrease in short interest in May. As of May 15th, there was short interest totaling 671,300 shares, a decrease of 20.7% from the April 30th total of 847,000 shares. Based on an average trading volume of 1,200 shares, the days-to-cover ratio is currently 559.4 days. View Zealand Pharma A/S's Short Interest. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) released its quarterly earnings data on Thursday, May, 11th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $1.96 million for the quarter. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 164.35% and a negative net margin of 1,140.99%. What is Zealand Pharma A/S's stock symbol? Zealand Pharma A/S trades on the OTCMKTS under the ticker symbol "ZLDPF." How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zealand Pharma A/S's stock price today? One share of ZLDPF stock can currently be purchased for approximately $38.25. How much money does Zealand Pharma A/S make? Zealand Pharma A/S (OTCMKTS:ZLDPF) has a market capitalization of $1.97 billion and generates $14.73 million in revenue each year. How many employees does Zealand Pharma A/S have? The company employs 355 workers across the globe. How can I contact Zealand Pharma A/S? Zealand Pharma A/S's mailing address is Sydmarken 11 Soborg, Copenhagen G7, 2860. The official website for the company is www.zealandpharma.com. The company can be reached via phone at 45-8877-3600, via email at investors@zealandpharma.com, or via fax at 45-8877-3898. This page (OTCMKTS:ZLDPF) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.